There were 886 press releases posted in the last 24 hours and 166,838 in the last 365 days.

Pioneering red light-activated anti-tumor prodrug reduces side effects

Dr Zhu Guangyu,Associate Professor from City University of Hong Kong developed an anti-cancer prodrug that can be controllably activated by red light "on-site".

HONG KONG, CHINA, October 11, 2019 / -- Most of the current clinical anti-tumor drugs used in chemotherapy move around in the patient's blood after intake and are unable to pinpoint the targeted tumor. Aiming to overcome this problem, Dr Zhu Guangyu, Associate Professor of Department of Chemistry, City University of Hong Kong (CityU) and his research team have recently developed phorbiplatin, an anti-cancer prodrug that can be controllably activated by red light. With its unique "on-site" activation characteristic, it will effectively kill cancer cells and minimize damage to normal tissues.

Phorbiplatin is a small-molecule platinum(IV) anti-cancer prodrug, shown to be inert in the dark but can be activated under low-power red-light irradiation. "Under short-period irradiation with low intensity of red light (650 nm, 7 mW/cm2) and without any external catalyst, phorbiplatin is reduced to oxaliplatin, a first-line clinical chemotherapeutic drug, as well as pyropheophorbide a (PPA), a photoactivation ligand. Both substances are effective in killing tumor cells," Dr Zhu explained the controllable activation property.

"Phorbiplatin is the first small-molecule platinum(IV) prodrug that can be activated by a red light," he added.

Unique photoreduction mechanism discovered

Previously, researchers utilized ultraviolet light to activate small-molecule platinum anti-tumor drugs. However, ultraviolet light has poor penetration depth and can also damage cells. On the contrary, "red light does not harm normal cells. And it possesses higher penetration depth through the skin to reach the subcutaneous tumor," Dr Zhu explained.

It took the team around 3 years to discover and study phorbiplatin, which is scaffolded on the molecular structure of oxaliplatin, a first-line anti-tumor drug widely used in the treatment of different cancers. The team functionlized oxaliplatin with PPA, which is a photosensitizer in photodynamic therapy and highly sensitive to red light, as the photoactive ligand to obtain phorbiplatin. Under irradiation with low intensity of red light, PPA acts as a "photo-induced redox relay" to transfer electrons from reducing agents to the platinum(IV) center to facilitate the reduction process, and as a result, releasing oxaliplatin.

Citing the statistics from the research, Dr Zhu said only in just 10 minutes, 81% of phorbiplatin was reduced rapidly to oxaliplatin and PPA. Phorbiplatin is controllably activated by red light in a spatial and temporal fashion and holds promise for minimizing the side effects originating from non-specific activation.

Significantly improved anti-tumor activity

The team also found that platinum-sensitive (A2780) human ovarian cancer cells treated with phorbiplatin under red light irradiation showed high fractions (68.0%) of dead cells. Compared with oxaliplatin, phorbiplatin displayed a remarkable ability to kill human breast cancer cells (MCF-7) with up to a 1,786-fold increase in photocytotoxicity, and a 974-fold increase for platinum-resistant (A2780cisR) human ovarian cancer cells.

Moreover, phorbiplatin with irradiation significantly inhibited tumor growth in mice, with 67% reduction in tumor volume and 62% reduction in tumor weight compared with mice treated with oxaliplatin, PPA, and even a mixture of oxaliplatin and PPA. The body weight of the mice treated with phorbiplatin did not change significantly, highlighting its safety.

Dr Zhu stressed that phorbiplatin is kinetically stable in the dark. In their toxicity tests, it indicated low toxicity to the normal human lung fibroblasts (MRC-5) in the dark. And for the mice treated with phorbiplatin under irradiation, their organs like heart and liver were in good conditions, further confirming the safety of phorbiplatin. On the contrary, there was liver damage in the mice treated directly with the mixture of oxaliplatin and PPA under irradiation.

A window for development of photoactivatable prodrugs

Dr Zhu suggested that the controllable activation property and superior anti-tumor activity of phorbiplatin significantly contribute to the development of photoactivatable anti-cancer prodrugs, especially platinum(IV) prodrugs that can be activated by red light, to reduce the adverse effects and conquer drug resistance of traditional platinum chemotherapy.

The research findings were published in the scientific journal Chem, titled "Phorbiplatin, a Highly Potent Pt(IV) Antitumor Prodrug That Can Be Controllably Activated by Red Light". Dr Zhu, together with Wang Zhigang, his Ph.D. student from CityU, are the corresponding authors of the paper. The first author is Wang Zhigang. Research team members are all from CityU, including Dr Ko Chi-Chiu and Dr Hajime Hirao, Associate Professors of Department of Chemistry, Dr Shi Peng, Associate Professor of Department of Biomedical Engineering as well.

Cynthia Wong
City University of Hong Kong
+852 3442 8916
email us here

Distribution channels: Healthcare & Pharmaceuticals Industry

EIN Presswire does not exercise editorial control over third-party content provided, uploaded, published, or distributed by users of EIN Presswire. We are a distributor, not a publisher, of 3rd party content. Such content may contain the views, opinions, statements, offers, and other material of the respective users, suppliers, participants, or authors.